Immunoassay Development for Leukemia Biomarkers

Leukemia biomarkers are critical molecular indicators used to diagnose, monitor, and predict the progression of leukemia, a group of cancers affecting blood and bone marrow. These biomarkers can include specific genes, proteins, or cellular changes that are associated with the disease. Common leukemia biomarkers include genetic mutations such as the BCR-ABL1 fusion gene in chronic myeloid leukemia (CML), surface antigens like CD19 in acute lymphoblastic leukemia (ALL), and elevated levels of certain enzymes or proteins detected in blood tests. The identification and analysis of these biomarkers are essential for early detection, tailoring personalized treatment plans, and evaluating patient responses to therapy. Furthermore, leukemia biomarkers facilitate the development of targeted therapies, improving outcomes and providing a deeper understanding of the pathophysiology of different leukemia subtypes.